196 related articles for article (PubMed ID: 25050880)
21. The synthesis and biological evaluation of multifunctionalised derivatives of noscapine as cytotoxic agents.
Debono AJ; Mistry SJ; Xie J; Muthiah D; Phillips J; Ventura S; Callaghan R; Pouton CW; Capuano B; Scammells PJ
ChemMedChem; 2014 Feb; 9(2):399-410. PubMed ID: 24339417
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents.
Mishra RC; Gundala SR; Karna P; Lopus M; Gupta KK; Nagaraju M; Hamelberg D; Tandon V; Panda D; Reid MD; Aneja R
Bioorg Med Chem Lett; 2015; 25(10):2133-40. PubMed ID: 25891106
[TBL] [Abstract][Full Text] [Related]
23. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.
Lopus M; Naik PK
Pharmacol Rep; 2015 Feb; 67(1):56-62. PubMed ID: 25560576
[TBL] [Abstract][Full Text] [Related]
24. Potent anti-inflammatory activity of novel microtubule-modulating brominated noscapine analogs.
Zughaier S; Karna P; Stephens D; Aneja R
PLoS One; 2010 Feb; 5(2):e9165. PubMed ID: 20161797
[TBL] [Abstract][Full Text] [Related]
25. A Novel Class of N-Sulfonyl and N-Sulfamoyl Noscapine Derivatives that Promote Mitotic Arrest in Cancer Cells.
Yong C; Devine SM; Gao X; Yan A; Callaghan R; Capuano B; Scammells PJ
ChemMedChem; 2019 Dec; 14(23):1968-1981. PubMed ID: 31714012
[TBL] [Abstract][Full Text] [Related]
26. Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids.
Santoshi S; Naik PK; Joshi HC
J Biomol Screen; 2011 Oct; 16(9):1047-58. PubMed ID: 21972248
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and biological evaluation of a cyclic ether fluorinated noscapine analog.
Aneja R; Vangapandu SN; Joshi HC
Bioorg Med Chem; 2006 Dec; 14(24):8352-8. PubMed ID: 17008104
[TBL] [Abstract][Full Text] [Related]
28. Rational design, synthesis and biological evaluations of amino-noscapine: a high affinity tubulin-binding noscapinoid.
Naik PK; Chatterji BP; Vangapandu SN; Aneja R; Chandra R; Kanteveri S; Joshi HC
J Comput Aided Mol Des; 2011 May; 25(5):443-54. PubMed ID: 21544622
[TBL] [Abstract][Full Text] [Related]
29. Structural Basis of Noscapine Activation for Tubulin Binding.
Oliva MA; Prota AE; Rodríguez-Salarichs J; Bennani YL; Jiménez-Barbero J; Bargsten K; Canales Á; Steinmetz MO; Díaz JF
J Med Chem; 2020 Aug; 63(15):8495-8501. PubMed ID: 32657585
[TBL] [Abstract][Full Text] [Related]
30.
Meher RK; Nagireddy PKR; Pragyandipta P; Kantevari S; Singh SK; Kumar V; Naik PK
J Biomol Struct Dyn; 2022 Sep; 40(15):6725-6736. PubMed ID: 33627059
[TBL] [Abstract][Full Text] [Related]
31. Insights into the structure and tubulin-targeted anticancer potential of N-(3-bromobenzyl) noscapine.
Cheriyamundath S; Mahaddalkar T; Reddy Nagireddy PK; Sridhar B; Kantevari S; Lopus M
Pharmacol Rep; 2019 Feb; 71(1):48-53. PubMed ID: 30465924
[TBL] [Abstract][Full Text] [Related]
32. 3-(3-Hydroxy-4-methoxyphenyl)-4-(3,4,5-trimethoxyphenyl)-1,2,5-selenadiazole (G-1103), a novel combretastatin A-4 analog, induces G2/M arrest and apoptosis by disrupting tubulin polymerization in human cervical HeLa cells and fibrosarcoma HT-1080 cells.
Zuo D; Guo D; Jiang X; Guan Q; Qi H; Xu J; Li Z; Yang F; Zhang W; Wu Y
Chem Biol Interact; 2015 Feb; 227():7-17. PubMed ID: 25529822
[TBL] [Abstract][Full Text] [Related]
33. Elucidation of the Tubulin-targeted Mechanism of Action of 9-(3-pyridyl) Noscapine.
Pradhan S; Mahaddalkar T; Choudhary S; Manhcukonda N; Nagireddy PR; Kantevari S; Lopus M
Curr Top Med Chem; 2017; 17(22):2569-2574. PubMed ID: 28056737
[TBL] [Abstract][Full Text] [Related]
34. Treatment of hormone-refractory breast cancer: apoptosis and regression of human tumors implanted in mice.
Aneja R; Zhou J; Zhou B; Chandra R; Joshi HC
Mol Cancer Ther; 2006 Sep; 5(9):2366-77. PubMed ID: 16985071
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and biological evaluation of noscapine analogues as microtubule-interfering agents.
Dai HL; Zheng JB; Lin M; Zheng J; Zhou FS; Dong XC; Guo L; Liu JW; Wen R
Yao Xue Xue Bao; 2012 Oct; 47(10):1347-57. PubMed ID: 23289148
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, in vitro antiproliferative activity and apoptosis-inducing studies of 1-(3',4',5'-trimethoxyphenyl)-3-(2'-alkoxycarbonylindolyl)-2-propen-1-one derivatives obtained by a molecular hybridisation approach.
Preti D; Romagnoli R; Rondanin R; Cacciari B; Hamel E; Balzarini J; Liekens S; Schols D; Estévez-Sarmiento F; Quintana J; Estévez F
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1225-1238. PubMed ID: 30141353
[TBL] [Abstract][Full Text] [Related]
37. Discovery of noscapine derivatives as potential β-tubulin inhibitors.
Nemati F; Salehi P; Bararjanian M; Hadian N; Mohebbi M; Lauro G; Ruggiero D; Terracciano S; Bifulco G; Bruno I
Bioorg Med Chem Lett; 2020 Oct; 30(20):127489. PubMed ID: 32784088
[TBL] [Abstract][Full Text] [Related]
38. Molecular modeling reveals binding interface of γ-tubulin with GCP4 and interactions with noscapinoids.
Suri C; Joshi HC; Naik PK
Proteins; 2015 May; 83(5):827-43. PubMed ID: 25662919
[TBL] [Abstract][Full Text] [Related]
39. Biological and pharmacological activities of noscapine: Focusing on its receptors and mechanisms.
Nourbakhsh F; Askari VR
Biofactors; 2021 Nov; 47(6):975-991. PubMed ID: 34534373
[TBL] [Abstract][Full Text] [Related]
40. Development of 9-(
Pragyandipta P; Naik MR; Bastia B; Naik PK
3 Biotech; 2023 Feb; 13(2):38. PubMed ID: 36636578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
